Kühne Holding completed the acquisition of Aenova from BC Partners.

Kühne Holding, a holding company, completed the acquisition of Aenova, a contract drug manufacturer, from BC Partners, a private equity firm. BC Partners will reinvest alongside Kühne Holding and continue to support Aenova as a minority shareholder. Financial terms were not disclosed. "With Kühne Holding, we have a strong partner for the further implementation of our strategy to make Aenova the leading CDMO with flexible capacities and innovative speciality platforms. We will continue to strengthen our competitive advantage in the production of conventional dosage forms while expanding in-demand technology platforms and development services to meet the future needs of our customers and thus provide patients worldwide with our services," Jan Kengelbach, Aenova CEO.